New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL
Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).